ClinicalTrials.gg
RecruitingNCT06572085Updated Nov 20, 2026

Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients

A Phase 4 interventional study of Butylphthalide and Sodium Chloride Injection and Saline Solution in Butylphthalide, Cardiac Arrest and Neuroprotective Drugs, sponsored by Tang Ziren. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Tang Ziren · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Jan 2022, registered Aug 2024).
  • Started Jan 2022; still recruiting 4 years 10 months later.
Updated Nov 20, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Heart Arrest with a site in China — 17 open to participants now, 22 under way, none of them phase 3. Heart Arrest · China.

Started
2022
with 1 other
Phase 4
2 of 37
2 open now
Primary completion
2029-12
later than 18 of 21 live
Registered
27th of 37
by date
Lead sponsor
5 of 37
Tang Ziren

Among the 37 studies in Heart Arrest with a site in China, this one is one of 2 that started in 2022, is one of 2 in phase 4, reaches primary completion later than 18 of the 21 other live ones, and was the 27th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

17 of the 37 studies in Heart Arrest with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Heart Arrest with a site in China, or all of them as a file.
02

Study summary

Cardiac arrest is one of the critical illnesses that is directly life-threatening, and patients who survive cardiac arrest develop severe neurological deficits or even die. The effectiveness of drugs to improve neurological function in resuscitated brain-injured patients has been a focus of research in the field of resuscitation. Butanephthalein has an ameliorating effect on the damage of central nervous function in patients with acute ischemic stroke, and can promote the improvement of patients' neurological deficits. On this basis, the present study was designed as a multicenter, prospective randomized controlled experiment, with internationally accepted methods for assessing near-term and long-term neurological function, to determine the effectiveness of butalbital in improving neurological function after cardiac arrest, with the aim of searching for new methods and ideas to improve neurological function and prognosis after cardiac arrest.

03

Conditions studied

  • Butylphthalide
  • Cardiac Arrest
  • Neuroprotective Drugs

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years old.
  2. Glasgow Coma Scale (GCS) scores ≤8 upon admission.
  3. Return of Spontaneous Circulation (ROSC) ≥30min.
  4. Signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Cardiac arrest due to irreversible causes such as trauma, poisoning, etc.
  2. Cardiac arrest due to end-stage conditions such as advanced cancer.
  3. Persistent cardiogenic shock that is unreversed (defined as a systolic blood pressure persistently \<90mmHg despite treatment with fluid resuscitation, vasopressor agents, and inotropic medications).
  4. Presence of pre-existing cerebrovascular disease prior to cardiac arrest or confirmed intracranial hemorrhage by CT scan following admission.
  5. Pre-existing CPC scores of 3-5 prior to cardiac arrest.
  6. Prior use of NBP or any medication containing NBP before cardiac arrest.
  7. Presence of severe hepatic or renal dysfunction before cardiac arrest (defined as ≥3× or ≥2× upper limit of normal creatinine).
  8. Bradycardia or sick sinus syndrome occurs after ROSC.
  9. History of prior drug or food allergies, or known allergies to the medication components used in this study.
  10. Existence of treatment limitations (patient or their legal representative refusing advanced life support treatment, including mechanical ventilation, chest compressions, targeted temperature management, etc.).
  11. Presence of severe bleeding tendency upon admission.
  12. Body temperature \<30℃ upon admission.
  13. Pregnant or lactating women, or reproductive-age females with elevated serum human Chorionic Gonadotropin (hCG) levels.
  14. Other conditions deemed unsuitable for this trial by the principal investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    Butylphthalide

    Butylphthalide and Sodium Chloride Injection 100ml ivgtt bid 14days

    Drug: Butylphthalide and Sodium Chloride Injection

  • Placebo comparator
    Saline Solution

    Saline Solution 100ml ivgtt bid 14days

    Drug: Saline Solution

Interventions

  • DrugButylphthalide and Sodium Chloride Injection

    Drug pages: ButylphthalideStudies of ButylphthalideButylphthalide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Sodium ChlorideStudies of Sodium ChlorideSodium Chloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.

  • DrugSaline Solution

    All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.

06

What researchers measure

Primary outcomes

  1. The proportion of patients with a Cerebral Performance Category (CPC) Score of 1-2

    The primary outcome is the proportion of patients with a Cerebral Performance Category (CPC) score of 1-2 at 6months after randomization in each group.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Starting 6 months after publication

Access criteria: The de-identified survey data will be made available for research purposes by contacting the corresponding authors

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2022 (actual). Primary completion is estimated for Dec 2029, 95 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Dec 2027 → Dec 2029 and completion Dec 2027 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2024
First posted
Aug 26, 2024
StartActual
Jan 1, 2022
Primary completionEst.
Dec 31, 2029was Dec 2027
CompletionEst.
Dec 31, 2029was Dec 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Beijing Chao-Yang Hospital · Beijing, China
Show 1 removed
  • Beijing Chao-Yang Hospital · Beijing, China
Nov 20, 2026
Primary completion
Dec 31, 2027→Dec 31, 2029
Nov 20, 2026
Study completion
Dec 31, 2027→Dec 31, 2029
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    1 site added, 1 site removed
    Show site
    • Beijing Chao-Yang Hospital · Beijing, China
    Show 1 removed
    • Beijing Chao-Yang Hospital · Beijing, China
    Primary completion Dec 31, 2027→Dec 31, 2029
    Study completion Dec 31, 2027→Dec 31, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06572085
Lead sponsor
Tang Ziren
Responsible party
Tang Ziren (Professor, Capital Medical University) — Sponsor-investigator
First posted
Aug 26, 2024
Start date
Jan 1, 2022
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Ziren Tang, Ph.D
Contact
tangziren1970@163.com
+86 010-85231530

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Butylphthalide · Sodium Chloride

Start the discussion